search
Back to results

Effect of Type 2 Diabetes Genetic Risk Information on Health Behaviors and Outcomes (TDE)

Primary Purpose

Diabetes Mellitus, Type 2

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Standardized Risk Assessment
Sponsored by
Duke University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Diabetes Mellitus, Type 2 focused on measuring predictive genomics, personalized medicine, personal genomics, genetic knowledge, genetic attitudes, prevention, health outcomes, behavioral

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Are male or female outpatients
  • No self-reported history of diabetes
  • No self-reported history of prior genetic testing for diabetes
  • Not pregnant (self report)
  • Are ≥18 and <81 years of age
  • Scheduled to receive serum glucose test in participating clinic
  • Fasting at time of blood draw (no food or drink - except water - previous 8 hours: self report)
  • Able and willing to give legally effective consent
  • Able and willing to participate in patient questionnaires
  • Ambulatory

Exclusion Criteria:

  • Previously or currently taking medications for lowering glucose (i.e., exenatide, pramlintide, metformin, rosiglitazone, pioglitazone, or future diabetes drugs) based on self-report and/or prescreening
  • Self-report of current or prior diabetes diagnosis
  • Self-reported prior history of genetic testing for diabetes
  • Baseline serum glucose test result >125

Sites / Locations

  • Duke Family Medicine at Pickens
  • Duke Health Center at Pickett Rd

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

No Intervention

No Intervention

Arm Label

SRA+genetic test

SRA only

no testing control

Arm Description

patients randomized to receive genetic test for type 2 diabetes risk will be followed and surveyed and will be counseled based on SAR and genetic risk for type 2 diabetes

Patients randomized to not get genetic testing will be followed and surveyed and will be counseled based on SRA only

Patients not interested in genetic testing will be followed and surveyed. Counseling will be based on SRA only

Outcomes

Primary Outcome Measures

Percentage of weight loss

Secondary Outcome Measures

Change in perceptions of personal risk for Type 2 diabetes
Change in HOmeostasis Model Assessment of Insulin Resistance (HOMA-IR)

Full Information

First Posted
February 22, 2009
Last Updated
April 9, 2014
Sponsor
Duke University
Collaborators
deCODE genetics
search

1. Study Identification

Unique Protocol Identification Number
NCT00849563
Brief Title
Effect of Type 2 Diabetes Genetic Risk Information on Health Behaviors and Outcomes
Acronym
TDE
Official Title
Effect of Type 2 Diabetes Genetic Risk Information on Health Behaviors and Outcomes
Study Type
Interventional

2. Study Status

Record Verification Date
April 2014
Overall Recruitment Status
Completed
Study Start Date
April 2009 (undefined)
Primary Completion Date
September 2011 (Actual)
Study Completion Date
June 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Duke University
Collaborators
deCODE genetics

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The primary objective of the study is to assess the clinical utility of a genetic test for Type 2 diabetes risk in combination with standardized risk assessment compared with standardized risk assessment alone, and to measure whether changes in perceived risk following genetic testing for Type 2 diabetes risk are correlated with behavior change and increased concern about risk for Type 2 diabetes.
Detailed Description
One thousand outpatients will be enrolled over two years at two university-affiliated primary care clinics. Patients will be assigned to one of three study arms: those who want genetic testing for diabetes risk will be randomly assigned to either receive the testing in addition to the SRA (SRA+G) or to receive the SRA only (SRA-only). Those who do not wish to have genetic testing will receive the SRA only. All patients will be surveyed at baseline, immediately after going through the SRA (risk-counseling visit; 2-4 weeks after initial visit), at 3 months post risk counseling visit and at 12 months post risk counseling visit. BMI, waist circumference, fasting plasma glucose and insulin will be measured at baseline and 12 months. Surveys will allow us to track patients' emotional responses to diabetes risk information and changing perceptions of personal risk for Type 2 diabetes over time, and to see if these correlate with subsequent diet and exercise behaviors. We will use a linear model to assess the effects of genetic testing among the three study groups, using HOmeostasis Model Assessment of Insulin Resistance (HOMA-IR) and weight loss as the primary outcomes. We will use generalized linear ordinal regression models to fit the ordinal survey outcomes of risk perceptions to the continuous HOMA-IR and weight outcome variables.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
Keywords
predictive genomics, personalized medicine, personal genomics, genetic knowledge, genetic attitudes, prevention, health outcomes, behavioral

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
450 (Actual)

8. Arms, Groups, and Interventions

Arm Title
SRA+genetic test
Arm Type
Active Comparator
Arm Description
patients randomized to receive genetic test for type 2 diabetes risk will be followed and surveyed and will be counseled based on SAR and genetic risk for type 2 diabetes
Arm Title
SRA only
Arm Type
No Intervention
Arm Description
Patients randomized to not get genetic testing will be followed and surveyed and will be counseled based on SRA only
Arm Title
no testing control
Arm Type
No Intervention
Arm Description
Patients not interested in genetic testing will be followed and surveyed. Counseling will be based on SRA only
Intervention Type
Other
Intervention Name(s)
Standardized Risk Assessment
Intervention Description
patients interested in genetic testing will be randomly assigned to either get testing for type 2 diabetes or not. All arms with receive standardized risk asessements. This study is evaluating behavior after receipt of genetic risk information and different types of counseling.
Primary Outcome Measure Information:
Title
Percentage of weight loss
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Change in perceptions of personal risk for Type 2 diabetes
Time Frame
12 months
Title
Change in HOmeostasis Model Assessment of Insulin Resistance (HOMA-IR)
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Are male or female outpatients No self-reported history of diabetes No self-reported history of prior genetic testing for diabetes Not pregnant (self report) Are ≥18 and <81 years of age Scheduled to receive serum glucose test in participating clinic Fasting at time of blood draw (no food or drink - except water - previous 8 hours: self report) Able and willing to give legally effective consent Able and willing to participate in patient questionnaires Ambulatory Exclusion Criteria: Previously or currently taking medications for lowering glucose (i.e., exenatide, pramlintide, metformin, rosiglitazone, pioglitazone, or future diabetes drugs) based on self-report and/or prescreening Self-report of current or prior diabetes diagnosis Self-reported prior history of genetic testing for diabetes Baseline serum glucose test result >125
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Geoffrey Ginsburg, Md, PhD
Organizational Affiliation
Institute for Genome Sciences and Policy, Duke University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Alex Cho, MD
Organizational Affiliation
Institute for Genome Sciences and Policy, Duke University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Scott Joy, MD
Organizational Affiliation
Duke University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Susanne Haga, PhD
Organizational Affiliation
Institute for Genome Sciences and Policy, Duke University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Isaac Lipkus, PhD
Organizational Affiliation
Institute for Genome Sciences and Policy, Duke University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Gloria Trujillo, MD
Organizational Affiliation
Duke University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Julianne O'Daniel, PhD
Organizational Affiliation
Institute for Genome Sciences and Policy, Duke University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Duke Family Medicine at Pickens
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27705
Country
United States
Facility Name
Duke Health Center at Pickett Rd
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27705
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
22302620
Citation
Waxler JL, O'Brien KE, Delahanty LM, Meigs JB, Florez JC, Park ER, Pober BR, Grant RW. Genetic counseling as a tool for type 2 diabetes prevention: a genetic counseling framework for common polygenetic disorders. J Genet Couns. 2012 Oct;21(5):684-91. doi: 10.1007/s10897-012-9486-x.
Results Reference
derived
PubMed Identifier
22257365
Citation
Cho AH, Killeya-Jones LA, O'Daniel JM, Kawamoto K, Gallagher P, Haga S, Lucas JE, Trujillo GM, Joy SV, Ginsburg GS. Effect of genetic testing for risk of type 2 diabetes mellitus on health behaviors and outcomes: study rationale, development and design. BMC Health Serv Res. 2012 Jan 18;12:16. doi: 10.1186/1472-6963-12-16.
Results Reference
derived

Learn more about this trial

Effect of Type 2 Diabetes Genetic Risk Information on Health Behaviors and Outcomes

We'll reach out to this number within 24 hrs